Patents by Inventor James Zangrilli

James Zangrilli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATING SEVERE ASTHMA IN PATIENTS WITH NASAL POLYPOSIS
    Publication number: 20230348606
    Abstract: Provided herein are methods of reducing exacerbations of asthma in an asthma patient with nasal polyposis, comprising administering to the patient an effective amount of the anti-interleukin-5 receptor (IL-5R) antibody benralizumab or an antigen-binding fragment thereof.
    Type: Application
    Filed: March 27, 2023
    Publication date: November 2, 2023
    Inventors: MARIA ESTHER GARCIA GIL, JAMES ZANGRILLI, ANNE BURDEN, JAMES KREINDLER
  • METHODS FOR TREATING SEVERE ASTHMA IN PATIENTS WITH NASAL POLYPOSIS
    Publication number: 20210380706
    Abstract: Provided herein are methods of reducing exacerbations of asthma in an asthma patient with nasal polyposis, comprising administering to the patient an effective amount of the anti-interleukin-5 receptor (IL-5R) antibody benralizumab or an antigen-binding fragment thereof.
    Type: Application
    Filed: June 4, 2021
    Publication date: December 9, 2021
    Inventors: Maria Esther GARCIA GIL, James ZANGRILLI, Anne Burden, James KREINDLER
  • Use of reslizumab to treat moderate to severe eosinophilic asthma
    Patent number: 10577414
    Abstract: Disclosed herein are methods of treating moderate to severe eosinophilic asthma in a patient comprising administering a therapeutically effective dose of reslizumab to the patient whose symptoms are inadequately controlled with a current asthma therapeutic and wherein the patient's blood eosinophil levels are equal to or greater than 400/?L.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: March 3, 2020
    Assignee: Cephalon, Inc.
    Inventors: Christopher O'Brien, James Zangrilli, Tushar Shah, Guy Brusselle
  • Inhalation Systems, Devices and Methods
    Publication number: 20180056018
    Abstract: Digital systems, devices and methods for managing a drug therapy, such as an anti-IL5 mAb or anti-IL5 receptor mAb treatment regimen for patients suffering from severe asthma (e.g., eosinophilic asthma), are provided. The digital systems, devices and methods may include hardware and software for predicting patient responses to a long term anti-IL5 mAb or anti-IL5 receptor mAb treatment based on clinical data obtained following an initial treatment period.
    Type: Application
    Filed: August 29, 2017
    Publication date: March 1, 2018
    Inventors: Janice M.G. Canvin, Marla D. Curran, Robert B. Noble, Saku JP Torvinen, James Zangrilli
  • Use of Reslizumab to Treat Moderate to Severe Eosinophilic Asthma
    Publication number: 20180030131
    Abstract: Disclosed herein are methods of treating moderate to severe eosinophilic asthma in a patient comprising administering a therapeutically effective dose of reslizumab to the patient whose symptoms are inadequately controlled with a current asthma therapeutic and wherein the patient's blood eosinophil levels are equal to or greater than 400/?L.
    Type: Application
    Filed: October 13, 2017
    Publication date: February 1, 2018
    Inventors: Christopher Obrien, James Zangrilli, Tushar Shah, Guy Brusselle
  • Use of reslizumab to treat moderate to severe eosinophilic asthma
    Patent number: 9815894
    Abstract: Disclosed herein are methods of treating moderate to severe eosinophilic asthma in a patient comprising administering a therapeutically effective dose of reslizumab to a patient whose symptoms are inadequately controlled with a current asthma therapeutic and wherein the patient's blood eosinophil levels are equal to or greater than 400/?L.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: November 14, 2017
    Assignee: Cephalon, Inc.
    Inventors: Christopher O'Brien, James Zangrilli, Tushar Shah
  • Use of Reslizumab To Treat Moderate to Severe Eosinophilic Asthma
    Publication number: 20160102144
    Abstract: Disclosed herein are methods of treating moderate to severe eosinophilic asthma in a patient comprising: 1) identifying a patient having moderate to severe eosinophilic asthma, wherein the patient's symptoms are inadequately controlled with a current asthma therapeutic and wherein the patient's blood eosinophil levels are equal to or greater than 400/?L; and 2) administering to said patient a therapeutically effective dose of reslizumab.
    Type: Application
    Filed: August 28, 2015
    Publication date: April 14, 2016
    Inventors: Christopher O'Brien, James Zangrilli, Tushar Shah, Guy Brusselle